APA (7th ed.) Citation

NA, B., A, S., V, S., MH, B., L, K., RI, D., . . . R, G. (2026). LY3410738, a Covalent Inhibitor of Mutant IDH1/2, is Effective in Acute Myeloid Leukemia Preclinical Models. Blood cancer discovery. https://doi.org/10.1158/2643-3230.BCD-25-0379

Chicago Style (17th ed.) Citation

NA, Brooks, et al. "LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models." Blood Cancer Discovery 2026. https://doi.org/10.1158/2643-3230.BCD-25-0379.

MLA (9th ed.) Citation

NA, Brooks, et al. "LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models." Blood Cancer Discovery, 2026, https://doi.org/10.1158/2643-3230.BCD-25-0379.